Literature DB >> 29215401

Relaxivity of Ferumoxytol at 1.5 T and 3.0 T.

Gesine Knobloch, Timothy Colgan, Curtis N Wiens, Xiaoke Wang, Tilman Schubert, Diego Hernando, Samir D Sharma, Scott B Reeder.   

Abstract

OBJECTIVES: The aim of this study was to determine the relaxation properties of ferumoxytol, an off-label alternative to gadolinium-based contrast agents, under physiological conditions at 1.5 T and 3.0 T.
MATERIALS AND METHODS: Ferumoxytol was diluted in gradually increasing concentrations (0.26-4.2 mM) in saline, human plasma, and human whole blood. Magnetic resonance relaxometry was performed at 37°C at 1.5 T and 3.0 T. Longitudinal and transverse relaxation rate constants (R1, R2, R2*) were measured as a function of ferumoxytol concentration, and relaxivities (r1, r2, r2*) were calculated.
RESULTS: A linear dependence of R1, R2, and R2* on ferumoxytol concentration was found in saline and plasma with lower R1 values at 3.0 T and similar R2 and R2* values at 1.5 T and 3.0 T (1.5 T: r1saline = 19.9 ± 2.3 smM; r1plasma = 19.0 ± 1.7 smM; r2saline = 60.8 ± 3.8 smM; r2plasma = 64.9 ± 1.8 smM; r2*saline = 60.4 ± 4.7 smM; r2*plasma = 64.4 ± 2.5 smM; 3.0 T: r1saline = 10.0 ± 0.3 smM; r1plasma = 9.5 ± 0.2 smM; r2saline = 62.3 ± 3.7 smM; r2plasma = 65.2 ± 1.8 smM; r2*saline = 57.0 ± 4.7 smM; r2*plasma = 55.7 ± 4.4 smM). The dependence of relaxation rates on concentration in blood was nonlinear. Formulas from second-order polynomial fittings of the relaxation rates were calculated to characterize the relationship between R1blood and R2 blood with ferumoxytol.
CONCLUSIONS: Ferumoxytol demonstrates strong longitudinal and transverse relaxivities. Awareness of the nonlinear relaxation behavior of ferumoxytol in blood is important for ferumoxytol-enhanced magnetic resonance imaging applications and for protocol optimization.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29215401      PMCID: PMC6143390          DOI: 10.1097/RLI.0000000000000434

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  24 in total

1.  A pilot investigation of new superparamagnetic iron oxide (ferumoxytol) as a contrast agent for cardiovascular MRI.

Authors:  Martin R Prince; Hong Lei Zhang; Shalini G Chabra; Paula Jacobs; Yi Wang
Journal:  J Xray Sci Technol       Date:  2003-01-01       Impact factor: 1.535

2.  Mathematical optimization of contrast concentration for T1-weighted spoiled gradient echo imaging.

Authors:  Scott B Reeder; Matthew R Smith; Diego Hernando
Journal:  Magn Reson Med       Date:  2015-05-18       Impact factor: 4.668

3.  Human whole-blood (1)H2O longitudinal relaxation with normal and high-relaxivity contrast reagents: influence of trans-cell-membrane water exchange.

Authors:  Gregory J Wilson; Mark Woods; Charles S Springer; Sarah Bastawrous; Puneet Bhargava; Jeffrey H Maki
Journal:  Magn Reson Med       Date:  2013-12-19       Impact factor: 4.668

4.  A Phase I Dosing Study of Ferumoxytol for MR Lymphography at 3 T in Patients With Prostate Cancer.

Authors:  Baris Turkbey; Harsh K Agarwal; Joanna Shih; Marcelino Bernardo; Yolanda L McKinney; Dagane Daar; Gary L Griffiths; Sandeep Sankineni; Linda Johnson; Kinzya B Grant; Juanita Weaver; Soroush Rais-Bahrami; Mukesh Harisinghani; Paula Jacobs; William Dahut; Maria J Merino; Peter A Pinto; Peter L Choyke
Journal:  AJR Am J Roentgenol       Date:  2015-07       Impact factor: 3.959

5.  Can Ferumoxytol be Used as a Contrast Agent to Differentiate Between Acute and Chronic Inflammatory Kidney Disease?: Feasibility Study in a Rat Model.

Authors:  Johannes Budjan; Sabine Neudecker; Daniel Schock-Kusch; Bettina Kraenzlin; Stefan O Schoenberg; Henrik J Michaely; Ulrike I Attenberger
Journal:  Invest Radiol       Date:  2016-02       Impact factor: 6.016

6.  FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease.

Authors:  Min Lu; Martin H Cohen; Dwaine Rieves; Richard Pazdur
Journal:  Am J Hematol       Date:  2010-05       Impact factor: 10.047

7.  Imaging aspirin effect on macrophages in the wall of human cerebral aneurysms using ferumoxytol-enhanced MRI: preliminary results.

Authors:  David M Hasan; Nohra Chalouhi; Pascal Jabbour; Vincent A Magnotta; David K Kung; William L Young
Journal:  J Neuroradiol       Date:  2013-02-18       Impact factor: 3.447

8.  Ferumoxytol for treating iron deficiency anemia in CKD.

Authors:  Bruce S Spinowitz; Annamaria T Kausz; Jovanna Baptista; Sylvia D Noble; Renuka Sothinathan; Marializa V Bernardo; Louis Brenner; Brian J G Pereira
Journal:  J Am Soc Nephrol       Date:  2008-06-04       Impact factor: 10.121

Review 9.  Emerging applications for ferumoxytol as a contrast agent in MRI.

Authors:  Mustafa R Bashir; Lubna Bhatti; Daniele Marin; Rendon C Nelson
Journal:  J Magn Reson Imaging       Date:  2014-06-30       Impact factor: 4.813

Review 10.  The emerging role of ferumoxytol-enhanced MRI in the management of cerebrovascular lesions.

Authors:  Nohra Chalouhi; Pascal Jabbour; Vincent Magnotta; David Hasan
Journal:  Molecules       Date:  2013-08-13       Impact factor: 4.411

View more
  26 in total

1.  Sensitivity of quantitative relaxometry and susceptibility mapping to microscopic iron distribution.

Authors:  Timothy J Colgan; Gesine Knobloch; Scott B Reeder; Diego Hernando
Journal:  Magn Reson Med       Date:  2019-08-18       Impact factor: 4.668

2.  Letter to the Editor: Intrapancreatic Accessory Spleen Masquerading as a Pancreatic Neuroendocrine Tumor.

Authors:  Victoria R Rendell; Matthias R Mühler; Emily R Winslow; Scott B Reeder
Journal:  J Gastrointest Surg       Date:  2019-05-31       Impact factor: 3.452

3.  Measurements of cerebral blood volume using quantitative susceptibility mapping, R2 * relaxometry, and ferumoxytol-enhanced MRI.

Authors:  Leonardo A Rivera-Rivera; Tilman Schubert; Kevin M Johnson
Journal:  NMR Biomed       Date:  2019-09-04       Impact factor: 4.044

4.  Rosette Trajectories Enable Ungated, Motion-Robust, Simultaneous Cardiac and Liver T2 * Iron Assessment.

Authors:  Adam M Bush; Christopher M Sandino; Shreya Ramachandran; Frank Ong; Nicholas Dwork; Evan J Zucker; Ali B Syed; John M Pauly; Marcus T Alley; Shreyas S Vasanawala
Journal:  J Magn Reson Imaging       Date:  2020-05-26       Impact factor: 4.813

5.  Ferumoxytol-enhanced vascular suppression in magnetic resonance neurography.

Authors:  Sophie C Queler; Ek Tsoon Tan; Christian Geannette; Martin Prince; Darryl B Sneag
Journal:  Skeletal Radiol       Date:  2021-05-07       Impact factor: 2.199

6.  Impact of ferumoxytol magnetic resonance imaging on the rhesus macaque maternal-fetal interface†.

Authors:  Sydney M Nguyen; Gregory J Wiepz; Michele Schotzko; Heather A Simmons; Andres Mejia; Kai D Ludwig; Ante Zhu; Kevin Brunner; Diego Hernando; Scott B Reeder; Oliver Wieben; Kevin Johnson; Dinesh Shah; Thaddeus G Golos
Journal:  Biol Reprod       Date:  2020-02-14       Impact factor: 4.285

7.  Preclinical hyperpolarized 129 Xe MRI: ventilation and T2 * mapping in mouse lungs at 7 T using multi-echo flyback UTE.

Authors:  Peter J Niedbalski; Alexander S Cochran; Teckla G Akinyi; Robert P Thomen; Elizabeth M Fugate; Diana M Lindquist; Ronald G Pratt; Zackary I Cleveland
Journal:  NMR Biomed       Date:  2020-04-14       Impact factor: 4.044

8.  Feasibility and optimization of ultra-short echo time MRI for improved imaging of IVC-filters at 3.0 T.

Authors:  Gesine Knobloch; Scott Nagle; Timothy Colgan; Tilman Schubert; Kevin M Johnson; Peter Bannas; Geng Li; Louis Hinshaw; James Holmes; Scott B Reeder
Journal:  Abdom Radiol (NY)       Date:  2021-01

9.  Comparison of gadolinium-enhanced and ferumoxytol-enhanced conventional and UTE-MRA for the depiction of the pulmonary vasculature.

Authors:  Gesine Knobloch; Timothy Colgan; Mark L Schiebler; Kevin M Johnson; Geng Li; Tilman Schubert; Scott B Reeder; Scott K Nagle
Journal:  Magn Reson Med       Date:  2019-06-22       Impact factor: 4.668

10.  A Radio-Nano-Platform for T1/T2 Dual-Mode PET-MR Imaging.

Authors:  Yaser Hadi Gholami; Hushan Yuan; Moses Q Wilks; Richard Maschmeyer; Marc D Normandin; Lee Josephson; Georges El Fakhri; Zdenka Kuncic
Journal:  Int J Nanomedicine       Date:  2020-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.